UK Government Help For Life Sciences Sector Is Welcomed, But Still Not Enough
This article was originally published in The Pink Sheet Daily
Therapeutic "clusters" are the next big idea, but unlikely to overshadow industry-academia tie-ups.
You may also be interested in...
Pharma and Academia: Finding New Ways to Join Hands for Mutual Benefit
As Big Pharmas seek to hedge their development risk and look for more externally sourced programs, partnerships with academic institutions are one of the many ingredients in the R&D secret sauce. Such deals aren't the academic-industry tie-ups of yore-where Big Pharma sought small money partnerships without giving a lot back to their academic partners. Business development execs view them as yet another way to access critically important innovation.
UK Life Sciences Package Includes "Innovation Pass" To Skirt NICE
LONDON - The UK 's Life Sciences Blueprint is an urgent bid to kick-start a sector that's increasingly important to the nation's future growth - especially in the light of the downturn in financial services
GSK Partners Leftover Assets With Academia
GlaxoSmithKline's Academic Drug Performance Unit isn't focused on what one might expect -trawling academic institutions for promising science and compounds to eventually bring into the fold